On May 9, 2018 Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD) a clinical-stage biopharmaceutical company focused on the development of CART-cell therapies, reported that the company will present recent advances in Celyad’s pipeline at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting being held May 16–19, 2018, in Chicago.
Poster presentations will highlight the recent developments of Celyad’s pipeline in autologous and allogeneic platforms to address cancers. The oral presentation will give updated data of the ongoing THINK Phase 1 trial with the case report of a CYAD-01 associated complete response in one relapsed/refractory AML patient, including observations concerning the modulation of systemic chemokines during the course of treatment.
David Gilham, VP of Research and Development at Celyad, commented: ‘Our presentations at the 2018 meeting of the ASGCT (Free ASGCT Whitepaper) will share our increasing knowledge around our lead NKG2D CAR T cell candidate along with discussing our pipeline including the B7H6 CAR T program and our allogeneic platform. These presentations are the culmination of an intensive level of activity within our R&D group. We anticipate that this will lead to a series of assets that will enter clinical stage testing during 2019.’
Presentation Details:
Title
Early Signs of Clinical Activity in AML Patients Receiving NKG2D CAR-T Cell Therapy in the Absence of Pre-Conditioning Chemotherapy: An Alternative Strategy to CAR-T Cell Therapy
Link
Number
967
Category
Cancer-Immunotherapy, Cancer Vaccines
Session
412 Advancements in T Cell-Based Therapies
Session Date & Time
Saturday, May 19, 2018, 11:00 AM CDT
Location
Continental Ballroom ABC
Posters Details:
Poster title
Functional screening of a B7H6 specific chimeric antigen receptor (CAR)
Link
Poster Number
123
Category
Cancer – Immunotherapy, Cancer Vaccines I
Session
Exhibit Hall Welcome Reception & Poster Session I
Session Date & Time
Wednesday, May 16, 2018, 5:30 PM CDT
Location
Stevens Salon C, D
Poster Title
Overcoming target-driven fratricide for CAR-T cell therapy
Link
Poster Number
119
Category
Cancer-Immunotherapy, Cancer Vaccines
Session
Exhibit Hall Welcome Reception & Poster Session I
Session Date & Time
Wednesday, May 16, 2018, 5:30 PM CDT
Location
Stevens Salon C, D
Poster Title
Expression of a TIM8 peptide reduces alloreactivity of T cells facilitating an allogeneic NKG2D Chimeric Antigen Receptor T cell therapy approach
Link
Poster Number
457
Category
Cell Therapies
Session
Exhibit Hall Networking Reception & Poster Session II
Session Date & Time
Thursday, May 17, 2018, 5:15 PM CDT
Location
Stevens Salon C, D